Antibe Therapeutics Inc. (TSXV:ATE) is pleased to announce the
submission of a Clinical Trial Application (“CTA”) to Health Canada for
its lead drug, ATB-346. The CTA proposes the initiation of a clinical
study entitled “A Double-Blind, Placebo-Controlled, Phase I Study to
Assess Safety, Tolerability and Pharmacokinetics of Single/Multiple
Ascending Doses of ATB-346 Orally Administered in Healthy Male and
Female Subjects.” The submission represents a significant milestone on a
well-defined pathway for the development of ATB-346.
Dan Legault, Antibe’s CEO, said “We are delighted to have advanced
efficiently to this stage in the development of ATB-346 and look forward
to further investigation of its pharmacokinetics and safety in healthy
human subjects in our planned Phase I clinical program scheduled to
begin this summer.”
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. develops safer medicines for pain and
inflammation. These medicines are based on Nobel Prize-winning medical
research highlighting the crucial role of gaseous mediators, chemical
substances produced in the human body to regulate a range of fundamental
cellular processes. The Corporation's drug design approach involves
chemically linking an existing off-patent drug ("base drug") to an
Antibe-patented, hydrogen sulfide-releasing molecule. For medical
conditions characterized by inflammation, pain or vascular dysfunction,
this design approach can efficiently produce improved versions of
existing drugs.
www.antibethera.com
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Copyright Business Wire 2014